Insulet downgraded to Neutral from Buy at Rothschild & Co Redburn

Rothschild & Co Redburn downgraded Insulet (PODD) to Neutral from Buy with a price target of $220, down from $380. The company’s distribution and product moats are “eroding,” the analyst tells investors in a research note. The firm believes Insulet’s “elevated expectations” leave the stock’s risk/reward skewed to the downside. The company’s slowing growth profile challenges its ability to sustain its premium multiple relative to the sector, contends Rothschild.